Mani Foroohar
Stock Analyst at Leerink Partners
(1.28)
# 2,333
Out of 4,479 analysts
147
Total ratings
38.16%
Success rate
-20.2%
Average return
Main Sectors:
Top Industries:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Outperform | $165 → $230 | $154.33 | +49.03% | 1 | Jun 24, 2024 | |
| NGNE Neurogene | Initiates: Outperform | $46 | $39.67 | +15.96% | 1 | Apr 29, 2024 | |
| CVAC CureVac | Downgrades: Market Perform | $12 → $4 | $3.36 | +19.23% | 2 | Apr 25, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $44 → $43 | $34.05 | +26.28% | 10 | Mar 18, 2024 | |
| RGNX REGENXBIO | Upgrades: Outperform | n/a | $10.80 | - | 7 | Mar 6, 2024 | |
| ENGN enGene Holdings | Initiates: Outperform | $31 | $8.89 | +248.71% | 1 | Feb 20, 2024 | |
| ALVR AlloVir | Downgrades: Market Perform | $1 | $0.74 | +36.05% | 9 | Dec 22, 2023 | |
| WVE Wave Life Sciences | Upgrades: Outperform | $12 | $5.21 | +130.33% | 4 | Dec 19, 2023 | |
| TNYA Tenaya Therapeutics | Initiates: Outperform | $7 | $3.10 | +125.81% | 1 | Nov 30, 2023 | |
| LXEO Lexeo Therapeutics | Initiates: Outperform | $19 | $14.53 | +30.76% | 1 | Nov 28, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Downgrades: Market Perform | $40 | $25.06 | +59.62% | 10 | May 12, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $25 → $27 | $25.07 | +7.70% | 11 | Apr 13, 2023 | |
| FDMT 4D Molecular Therapeutics | Maintains: Market Perform | $14 → $13 | $20.49 | -36.54% | 7 | Apr 13, 2023 | |
| MRNA Moderna | Downgrades: Underperform | $111 → $93 | $115.84 | -19.72% | 16 | Feb 24, 2023 | |
| IONS Ionis Pharmaceuticals | Maintains: Market Perform | $34 → $27 | $45.32 | -40.42% | 11 | Feb 23, 2023 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $9 → $8 | $7.11 | +12.52% | 6 | Jan 23, 2023 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $50 → $49 | $20.41 | +140.14% | 9 | Jan 23, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $86 → $84 | $21.82 | +284.97% | 4 | Jan 23, 2023 | |
| EDIT Editas Medicine | Maintains: Market Perform | $6 → $7 | $4.47 | +56.77% | 4 | Jan 23, 2023 | |
| BLUE bluebird bio | Maintains: Market Perform | $9 → $8 | $0.97 | +724.74% | 7 | Jan 23, 2023 | |
| BEAM Beam Therapeutics | Maintains: Outperform | $81 → $77 | $22.38 | +244.06% | 2 | Jan 23, 2023 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Market Perform | $144 → $143 | $247.57 | -42.24% | 8 | Jan 23, 2023 | |
| ABEO Abeona Therapeutics | Maintains: Market Perform | $5 → $6 | $4.12 | +45.63% | 4 | Nov 14, 2022 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $75 → $76 | $52.68 | +44.28% | 1 | Nov 7, 2022 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $30 → $34 | $1.55 | +2,100.65% | 4 | May 12, 2022 | |
| ADVM Adverum Biotechnologies | Maintains: Market Perform | $50 → $20 | $6.90 | +189.86% | 6 | Jul 23, 2021 |
Sarepta Therapeutics
Jun 24, 2024
Maintains: Outperform
Price Target: $165 → $230
Current: $154.33
Upside: +49.03%
Neurogene
Apr 29, 2024
Initiates: Outperform
Price Target: $46
Current: $39.67
Upside: +15.96%
CureVac
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $3.36
Upside: +19.23%
Mirum Pharmaceuticals
Mar 18, 2024
Maintains: Outperform
Price Target: $44 → $43
Current: $34.05
Upside: +26.28%
REGENXBIO
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $10.80
Upside: -
enGene Holdings
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $8.89
Upside: +248.71%
AlloVir
Dec 22, 2023
Downgrades: Market Perform
Price Target: $1
Current: $0.74
Upside: +36.05%
Wave Life Sciences
Dec 19, 2023
Upgrades: Outperform
Price Target: $12
Current: $5.21
Upside: +130.33%
Tenaya Therapeutics
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $3.10
Upside: +125.81%
Lexeo Therapeutics
Nov 28, 2023
Initiates: Outperform
Price Target: $19
Current: $14.53
Upside: +30.76%
Arrowhead Pharmaceuticals
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $25.06
Upside: +59.62%
BridgeBio Pharma
Apr 13, 2023
Maintains: Outperform
Price Target: $25 → $27
Current: $25.07
Upside: +7.70%
4D Molecular Therapeutics
Apr 13, 2023
Maintains: Market Perform
Price Target: $14 → $13
Current: $20.49
Upside: -36.54%
Moderna
Feb 24, 2023
Downgrades: Underperform
Price Target: $111 → $93
Current: $115.84
Upside: -19.72%
Ionis Pharmaceuticals
Feb 23, 2023
Maintains: Market Perform
Price Target: $34 → $27
Current: $45.32
Upside: -40.42%
Recursion Pharmaceuticals
Jan 23, 2023
Maintains: Market Perform
Price Target: $9 → $8
Current: $7.11
Upside: +12.52%
Rocket Pharmaceuticals
Jan 23, 2023
Maintains: Outperform
Price Target: $50 → $49
Current: $20.41
Upside: +140.14%
Intellia Therapeutics
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $21.82
Upside: +284.97%
Editas Medicine
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $4.47
Upside: +56.77%
bluebird bio
Jan 23, 2023
Maintains: Market Perform
Price Target: $9 → $8
Current: $0.97
Upside: +724.74%
Beam Therapeutics
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $22.38
Upside: +244.06%
Alnylam Pharmaceuticals
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $247.57
Upside: -42.24%
Abeona Therapeutics
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $4.12
Upside: +45.63%
CRISPR Therapeutics AG
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $52.68
Upside: +44.28%
Caribou Biosciences
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.55
Upside: +2,100.65%
Adverum Biotechnologies
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $6.90
Upside: +189.86%